Couve Japonesa Review: VSL Breakdown, Claims, and Science

2. What Couve Japonesa Is

Based on the transcript, Couve Japonesa is presented less as a conventional supplement brand and more as a natural vision protocol built around Japanese kale juice. The phrase itself means Japanese kale in Portuguese, and the VSL uses that cultural frame deliberately. Japanese origin cues have long been valuable in health copy because they suggest longevity, tradition, discipline, and secrets preserved outside Western medicine. Here, the product is not introduced as a bottle of capsules with a supplement facts panel. It is introduced as a simple juice capable of waking dormant regenerative activity inside the eye.

The VSL says this effect comes from combining four natural ingredients, but the excerpt does not identify the four ingredients, their amounts, their preparation method, their sourcing, or their clinical rationale. That omission is important. A buyer hearing the story may remember the emotional handle, Japanese kale juice, while the actual commercial product may be a recipe guide, digital protocol, supplement, powdered drink, or bundle. Without a disclosed label or offer page, the safest description is this: Couve Japonesa is a direct-response vision offer that uses Japanese kale as the named hero ingredient and sells the idea of natural ocular regeneration.

That distinction matters for affiliates. If the conversion page eventually reveals a low-ticket recipe, the claims still need substantiation because the advertising promise is health-related. If it sells a dietary supplement, the claims become even more sensitive because disease-adjacent language around macular degeneration, cataracts, and reversal can cross regulatory lines quickly. If it sells information only, the copy still creates consumer expectations about a health outcome. The format does not erase the claim.

The product identity is also built through what it opposes. Couve Japonesa is defined against progressive glasses, temporary drops, expensive procedures, and repeated eye appointments. The script tells the viewer these options only treat symptoms and may even accelerate tissue weakening. That is an aggressive positioning choice. It makes the product feel like a root-cause alternative rather than another eye-health aid. It also risks making conventional care look not merely incomplete, but harmful or commercially corrupt.

From a messaging standpoint, the name does useful work. It is concrete enough to feel discoverable and simple enough to remember. It avoids sounding like a synthetic compound or pharmaceutical intervention. It also allows the copy to blend food familiarity with exotic novelty. Kale is recognizable; Japanese kale is intriguing. Juice feels safe; regeneration feels advanced. The VSL lives in that contrast. It asks the prospect to accept that something ordinary, when found in the right cultural or scientific context, can produce extraordinary results. That is a classic direct-response bridge from skepticism to curiosity.

3. The Problem It Targets

The stated target is not one single diagnosis. The VSL gathers a wide cluster of vision complaints under the umbrella of age-related decline and inactive regenerative cells. It mentions people over 60, decades of glasses, discouraging diagnoses, blurry text, difficulty recognizing faces, trouble reading medicine labels, bright-light discomfort, night driving fear, headaches from screens, eye strain, cataracts, and macular degeneration. This broad targeting expands the market, but it also creates medical ambiguity. A viewer with refractive error, dry eye, cataract, diabetic retinopathy, glaucoma, or age-related macular degeneration may hear the same promise even though these conditions have different causes and different standards of care.

The strongest emotional problem in the transcript is dependence. The viewer is invited to imagine being free from lenses, appointments, invasive procedures, and the embarrassment of not seeing details on a phone or a loved one’s face. The script understands that vision loss is not experienced as an abstract medical issue. It is experienced in small humiliations: road signs look foggy, labels become stressful, cooking becomes harder, and social recognition becomes uncertain. Sarah’s story is designed around that erosion. She does not merely have a diagnosis. She withdraws, cries alone, and loses the independence that defined her.

For older prospects, this is potent because declining eyesight threatens autonomy. A copywriter could sell this offer around acuity alone, but the VSL sells identity restoration. The phrase about reclaiming freedom, self esteem, and independence is not filler. It is the emotional thesis. The product is framed as a way to stay capable, useful, mobile, and connected. That is a deeper desire than reading an eye chart.

The risk is that the VSL compresses very different problems into one cause. Glasses correct refractive errors such as nearsightedness and astigmatism; cataracts involve clouding of the lens; age-related macular degeneration damages central retinal vision; glaucoma affects the optic nerve; dry eye and screen strain have their own mechanisms. The transcript implies that all of these may be tied to dormant regenerative cells waiting for the right natural stimulus. That is a clean selling idea, but real eye disease is messier.

There is also a meaningful compliance issue in how the problem is framed. The script states that doctors say there is no cure for macular degeneration and then offers a natural protocol as the turning point. Even if it never uses the exact word cure for the product, the surrounding implication is that the product can reverse or materially improve serious disease. Affiliates need to treat that as a red-flag zone. In health copy, implication carries weight. A viewer does not parse claims like a lawyer. They hear, my diagnosis may not be final.

4. How It Works - The Proposed Mechanism

The VSL’s proposed mechanism is ocular regeneration through dormant cells. According to the script, researchers at Harvard Medical School discovered that the real root of vision loss lies in the inactivity of regenerative cells already inside the eye. These cells are described as tiny engineers ready to repair damage, but over time they fall asleep. The solution, the VSL says, is to wake them naturally with a combination of four ingredients, thereby reactivating the eye’s own regenerative process without surgery, drops, or invasive procedures.

As a piece of copy, the mechanism is elegant. It offers a physical explanation that feels more advanced than vitamins and more hopeful than symptom management. It also solves a common supplement-copy problem: viewers are skeptical that ordinary nutrients can make a dramatic difference. The script sidesteps that by saying the nutrients are not doing the repair directly. They are triggering a built-in biological system. That makes the protocol sound catalytic. A small daily act can supposedly unlock a large internal response.

The mechanism also functions as a bridge between science and simplicity. Harvard supplies institutional authority. Regenerative cells supply novelty. Japanese kale juice supplies accessibility. The prospect does not need to understand retinal biology. They only need to accept a metaphor: the eye has repair cells, aging makes them dormant, and this protocol wakes them. That metaphor is memorable, emotionally satisfying, and easy for affiliates to echo in advertorials or presell pages.

The problem is that the transcript leaps from experimental regenerative science to consumer-ready dietary action. There is legitimate research into retinal regeneration, stem-cell approaches, gene therapy, cell reprogramming, and retinal repair pathways. That does not mean a juice or undisclosed blend can regenerate human retina cells or reverse macular degeneration. Scientific plausibility in a distant field is not product proof. A mechanism claim needs evidence that the actual ingredients, at the actual dose, in the actual user population, produce the advertised outcomes.

The wording also blurs cell types. The eye contains many specialized tissues: cornea, lens, retina, macula, optic nerve, photoreceptors, retinal pigment epithelium, ganglion cells, and supporting glia. A claim about waking regenerative cells inside the eyes is too broad unless the VSL identifies which cells, what pathway, what biomarker, and what clinical endpoint. Are viewers improving visual acuity? Contrast sensitivity? Night vision? Drusen progression? Lens opacity? Refractive error? The transcript does not say.

That lack of specificity is strategically useful but scientifically weak. A vague mechanism can absorb many symptoms, but it cannot be tested cleanly. For affiliates, the key question is whether the offer page supplies the missing details. If it does not, the mechanism should be treated as a persuasion device rather than a substantiated explanation.

5. Key Ingredients & Components

The named component is Japanese kale juice. The transcript also says four natural ingredients are combined to reactivate ocular regeneration, but the excerpt does not disclose the other three. That is a significant limitation for any serious review. A product cannot be evaluated as a formula if the formula is hidden. We can analyze the ingredient story the VSL uses, but we cannot verify safety, dosing, interactions, standardization, or clinical relevance without the actual ingredient list.

Kale and related leafy greens do have a credible nutritional association with eye health. They can contain carotenoids such as lutein and zeaxanthin, along with vitamin C, vitamin K, beta-carotene precursors, folate, minerals, and polyphenols. Lutein and zeaxanthin are relevant because they accumulate in the macula and are part of the broader nutrition conversation around age-related macular degeneration. But that is a long way from saying a Japanese kale juice can restore vision or make glasses unnecessary. Nutrition support is not the same as anatomical regeneration.

The VSL’s ingredient strategy relies on the halo effect of naturalness. It says simple, safe, and 100% natural. In direct response, naturalness can reduce perceived risk, especially when the alternative frame is surgery, injections, drops, and expensive clinic care. But natural does not automatically mean effective, clinically tested, or appropriate for every older adult. Leafy greens high in vitamin K may matter for people taking anticoagulant medication. Concentrated extracts can behave differently from food portions. If the product includes other botanicals, stimulants, minerals, or fat-soluble nutrients, interactions and tolerability become more relevant.

Copywriters should also notice the absence of dosage language. The story says two weeks, thousands of people, and dramatic improvement, but does not tell us how much juice, how often, in what form, or for which condition. Those details matter because ingredient claims are dose-dependent. A food may contain a helpful compound without providing enough of it in a practical serving to change a clinical outcome. Conversely, a concentrated product may provide a meaningful dose but introduce safety considerations.

The four-ingredient phrase is a useful curiosity hook. It tells the viewer there is a recipe or protocol coming and creates an open loop: what are the four ingredients? That can improve retention through the VSL. It also lets the pitch feel proprietary without sounding synthetic. The viewer imagines a kitchen-simple combination that medicine overlooked.

Editorially, the right verdict is cautious. Japanese kale can be part of a healthy diet, and greens can support general health. But the VSL’s larger claim is not that kale is nutritious. It is that a specific combination wakes regenerative cells and reverses vision decline. Without ingredient disclosure and controlled human data, that remains unproven.

6. Persuasion Hooks & Ad Psychology

This VSL uses a dense stack of direct-response hooks, but they are not random. The first is the senior transformation hook: thousands of people over 60 are seeing clearly again. That line immediately selects the audience and establishes scale. It also turns a personal health worry into a social phenomenon. If thousands are doing it, the viewer feels late rather than fringe.

The second hook is the suppressed secret. The transcript says the secret was kept from the public for decades, that doctors who tried to share findings were discouraged, that scientific publications were censored, and that protocols were shelved because the process was too simple and unprofitable. This is not merely anti-establishment flavor. It gives the viewer an explanation for why they have not heard of the solution before. That is vital when the promise is extraordinary. If the answer is simple, the natural objection is, why did my doctor not tell me? The VSL answers: because the system benefits from temporary solutions.

The third hook is contrast. Glasses, drops, procedures, and appointments are framed as expensive, temporary, and symptom-focused. Couve Japonesa is framed as simple, natural, accessible, and root-cause. The contrast is emotionally efficient because it turns ordinary medical care into an antagonist. The viewer is not just choosing a product. They are choosing whether to stay dependent or activate what the body already knows how to do.

The fourth hook is vivid future pacing. The VSL asks the viewer to imagine waking up without light sensitivity, reading medicine labels clearly, driving at night without fear, and seeing every detail in a loved one’s eyes. These scenes are specific and practical. They avoid abstract wellness language and put the benefit into daily life. That is good copy. The strongest health VSLs often sell micro-moments of restored normalcy rather than grandiose lifestyle upgrades.

The fifth hook is borrowed authority. Harvard Medical School, Johns Hopkins, clinical pharmacology, pharmaceutical research, and unnamed recent studies create an authority stack. A prospect may not check the details. They simply feel surrounded by signals of expertise. The pitch then adds testimonials to make the science feel lived-in. One person says the eyes felt as if they were waking from deep sleep. Another claims to see better at 60 than at 30 despite nearsightedness and astigmatism.

The final hook is countdown-style immediacy. The phrase in the next two minutes suggests the viewer is close to a reveal. It lowers the psychological cost of continuing. For affiliates, this VSL is a reminder that retention often comes from sequential curiosity, not one big promise. The audience is carried from phenomenon to conspiracy to mechanism to personal story to imminent reveal.

7. The Psychology Behind The Pitch

The emotional engine of the Couve Japonesa VSL is loss aversion. People fear losing eyesight more intensely than they desire a vague improvement in wellness. The script keeps the viewer close to that fear without letting it become hopeless. It names the everyday losses: medicine labels, phone text, road signs, faces, cooking, independence, and night driving. Then it reframes the fear as reversible. That oscillation between threat and relief is classic VSL pacing.

The second psychological driver is authority conflict. The hero, Joseph Brown, is positioned as a medical insider who breaks from the limits of official medicine because his wife is suffering. That matters because skeptical health prospects often distrust both anonymous supplement sellers and cold institutional messaging. The insider-whistleblower figure solves both problems. He has credentials, but he is emotionally motivated. He knows the system, but he is no longer obedient to it. The wife’s diagnosis gives him moral permission to challenge the consensus.

The VSL also uses what might be called biological ownership. It tells prospects the solution is already inside their eyes. That is psychologically appealing because it reduces dependency on the seller. The product is not portrayed as an artificial crutch. It is the key to a latent self-repair process. This makes the buyer feel less like a patient and more like someone reclaiming an ability that was wrongly dismissed.

Another strong psychological move is dignity restoration. The transcript does not dwell only on seeing better. It says the viewer can reclaim freedom, self esteem, and independence. Those words speak to shame. Older people with vision loss may feel vulnerable, burdensome, or diminished. By linking the product to dignity, the pitch widens the value of the outcome. A bottle, recipe, or protocol becomes emotionally priced against autonomy.

The VSL also neutralizes skepticism by admitting disbelief. It says the claim might sound hard to believe. That is a useful inoculation technique. Instead of waiting for the viewer to object, the script voices the objection and then answers it with social proof: this is exactly what is happening for thousands. That transition does not prove the claim, but it keeps the narrative moving.

For copywriters, the most instructive part is the layering of specificity and vagueness. The daily-life symptoms are highly specific. The scientific mechanism is broad. The personal story is vivid. The clinical evidence is unnamed. This balance lets the pitch feel concrete while avoiding details that could invite deeper scrutiny. It is effective persuasion, but it is also where responsible affiliates should slow down. When the emotional scenes are precise and the proof is general, the copy may be stronger than the substantiation.

8. What The Science Says

The scientific backdrop is more nuanced than the VSL suggests. Yes, eye health is influenced by age, nutrition, oxidative stress, vascular health, genetics, smoking, diabetes, and other factors. Yes, serious researchers are studying retinal repair, cell therapy, gene therapy, and reprogramming. But no, the evidence available from major public sources does not support the broad consumer claim that a Japanese kale juice can regenerate human eyes, reverse macular degeneration, eliminate glasses, or work for anyone regardless of age.

The strongest mainstream nutrition evidence in this area is not about kale juice. It is the AREDS and AREDS2 work from the National Eye Institute. The National Eye Institute explains that AREDS2 supplements can help slow vision loss in people with intermediate age-related macular degeneration in one or both eyes. That is meaningful, but it is also narrower than the Couve Japonesa promise. AREDS2 is a specific high-dose formulation, not a general reversal protocol, and it is not presented as a cure or as a way to stop needing glasses.

The VSL’s Harvard-style regeneration language appears to echo real experimental research, but the bridge is weak. A peer-reviewed Nature paper indexed on PubMed reported that epigenetic reprogramming in mouse retinal ganglion cells restored youthful molecular patterns, promoted axon regeneration after injury, and improved visual function in mouse models. That is fascinating science. It is also gene-therapy-adjacent laboratory work in animals, not evidence that orally consumed kale can reactivate human retinal regeneration. Using such research as a broad proof umbrella for a juice-based consumer offer would be a major extrapolation.

Public-health context also argues for care. The CDC identifies cataract, diabetic retinopathy, glaucoma, and age-related macular degeneration as major causes of blindness and low vision among adults. These are not interchangeable complaints. They require diagnosis and monitoring. Some, such as wet macular degeneration or glaucoma, can worsen permanently if people delay evidence-based care.

The transcript’s claim that traditional treatments may speed the weakening of eye tissues is especially serious. The excerpt does not provide evidence for that claim. It is one thing to say glasses do not treat a root cause of retinal disease; it is another to imply that standard care causes deterioration. That kind of statement needs strong proof because it could push vulnerable viewers away from clinicians.

Scientifically, the fair position is this: leafy greens can be part of an eye-conscious diet, and certain nutrients have evidence for specific contexts. Regenerative eye research is real but still complex, experimental, and condition-specific. Couve Japonesa’s VSL collapses those facts into a much larger promise. Until the product can show controlled human outcomes for the exact protocol, the regeneration and reversal claims should be treated as unsupported.

9. Offer Structure & Urgency Mechanics

The excerpt does not show the final checkout page, price stack, guarantees, upsells, order bumps, or scarcity timer, but the early VSL reveals the likely offer architecture. The pitch is built around delayed disclosure. It promises that in the next two minutes the viewer will learn exactly how the discovery was made and how to start using it today. That means the video is using curiosity retention before it gets to the commercial details. The viewer is held by the question of what the four ingredients are, how Joseph found them, and whether Sarah’s vision was saved.

The urgency is not initially a discount deadline. It is medical and emotional urgency. Sarah is going blind fast. The viewer may be losing independence. Doctors can only slow the process. If regenerative cells are dormant, every day feels like further missed repair. That kind of urgency can be more powerful than a countdown timer because it is rooted in fear of irreversible decline. The VSL does not need to say buy before midnight in the excerpt; it says the turning point could be today.

The offer also appears to be designed as an alternative-path purchase. Standard options are framed as costly, temporary, and dependent: progressive glasses, drops, procedures, appointments, specialty clinics. Couve Japonesa is framed as simple, safe, natural, and accessible. This creates a value comparison before price is even introduced. If a prospect believes the alternative is years of appointments or expensive intervention, a recipe, supplement, or protocol can feel inexpensive even at a premium direct-response price.

Affiliates should look for two things on the actual offer page. First, does the sales page shift from disease-level VSL promises to more modest structure-function language at checkout? That gap can create compliance risk. Second, does the page use scarcity that is real or merely theatrical? Health buyers under fear are more susceptible to urgency, so fake inventory claims, expiring bonuses, or aggressive exit discounts can damage trust and raise scrutiny.

The VSL also uses time-to-result urgency. One testimonial says improvement began within two weeks. That is a conversion accelerant because it shortens the perceived wait. Older buyers may not want a six-month nutritional experiment. They want near-term signs that their eyesight is waking up. But fast-results language should be supported by data. If the only evidence is anecdotal, marketers should avoid presenting two weeks as a typical expectation.

A compliant version of this offer would separate hope from certainty. It would state who the protocol is for, what outcomes are realistic, what conditions require medical care, what the product is not intended to do, and how refunds work. The current excerpt leans into urgency through vulnerability. That can sell, but it needs careful guardrails.

10. Social Proof & Authority Claims

The VSL stacks authority before it asks for belief. Harvard Medical School appears early as the institution behind the alleged discovery of dormant regenerative cells. Joseph Brown then enters as a doctor, Johns Hopkins graduate, clinical pharmacology specialist, and long-time senior researcher at a major pharmaceutical company. These details are designed to make the pitch feel medically serious rather than folk-remedy casual.

For editorial purposes, every one of those authority claims should be treated as unverified unless the sales page provides documentation. A real doctor can usually be connected to a license, publications, institutional profile, alumni record, hospital affiliation, or professional history. A real senior pharmaceutical researcher often leaves a trail in patents, publications, conference materials, or company records. The transcript excerpt provides none of that. It simply asserts the credentials. That does not make them false, but it means affiliates should not repeat them as verified facts without checking.

The Sarah story is the emotional authority layer. It turns Joseph from expert into husband. That is a deliberate credibility move. A medical professional solving his own family crisis feels more trustworthy than a marketer selling to strangers. It also reframes the discovery as reluctant and personal. He was not looking for a product. He was trying to save the woman he loved. That structure is common in health VSLs because it gives the creator a noble motive and a reason to challenge conventional advice.

The testimonials are vivid but thinly evidenced. One person says vision became more vivid and clear within two weeks, like eyes waking from sleep. Another says he had nearsightedness and astigmatism since adolescence, could barely walk without glasses at 60, and now sees better than at 30. That second testimonial is particularly aggressive because nearsightedness and astigmatism are refractive issues. A claim of seeing better than age 30 implies a measurable improvement that should be documentable through eye exams. The transcript does not provide those records.

The VSL also uses crowd proof: thousands of people, men and women in their 70s and 80s, and improvements doctors cannot explain. Crowd proof can lower resistance, but it is weak unless the marketer can show how the number was derived. Were these verified purchasers? Survey respondents? Clinical participants? Before-and-after eye tests? Refund-resistant testimonials? The viewer is not told.

For affiliates, the practical rule is simple. Testimonials can support a story, but they cannot carry a disease or reversal claim by themselves. If the VSL promises eye regeneration, the proof burden is not a handful of emotional quotes. It is controlled evidence, transparent endpoints, and clear disclosure of typical results. The current authority stack is persuasive, but the excerpt leaves too much unverified.

11. FAQ & Common Objections

This VSL anticipates several objections without presenting them as formal questions. A useful review should surface them directly, because these are the questions a careful buyer, affiliate, or compliance reviewer should ask before promoting the offer.

• Is Couve Japonesa proven to reverse vision loss? The excerpt does not provide controlled human evidence for the product. It references studies, Harvard, and testimonials, but it does not show a trial on the exact protocol. Based on the transcript alone, reversal claims are unsupported.
• Can Japanese kale support eye health? Leafy greens can contain nutrients relevant to general eye health, including carotenoids. That supports a modest nutrition story. It does not prove regeneration, independence from glasses, or improvement in macular degeneration.
• Does the VSL prove that doctors hid the discovery? No. The transcript alleges censorship, discouraged doctors, and shelved protocols, but provides no names, publications, dates, or documented suppression. This is a persuasion hook, not substantiated evidence in the excerpt.
• Is it safe because it is natural? Not automatically. Food-like ingredients may be safe for many people, but concentrated formulas, high vitamin K foods, botanicals, minerals, or unknown additives can matter for people on medication or with chronic disease. The formula must be disclosed before safety can be assessed.
• Should someone stop eye drops, injections, glasses, or scheduled appointments? No responsible interpretation of this transcript supports stopping medical care. Vision conditions can progress silently or permanently. Any buyer with diagnosed eye disease should keep working with an eye-care professional.
• Are the testimonials enough? They are not enough for the claims being made. Anecdotes can illustrate user experience, but dramatic vision changes should be supported with eye-test records, diagnosis details, time frames, and typical-results disclosures.
• Is the Joseph Brown authority claim verified? Not from the excerpt. The credentials may be part of the sales story, but affiliates should verify licensing, education, publications, or professional history before presenting him as a confirmed medical authority.
• What is the biggest copy risk? The biggest risk is the movement from eye-health support into disease reversal. Mentions of macular degeneration, cataracts, and regenerative cells raise the evidentiary burden dramatically.

The most common buyer objection will be, if this works, why have I never heard of it? The VSL answers with a conspiracy frame. A more evidence-based answer would be: because nutrition, eye disease, and retinal regeneration are active research areas, but most promising mechanisms do not translate into simple consumer cures. That answer is less exciting, but it is more honest.

12. Final Take - Balanced Verdict

Couve Japonesa is a strong VSL from a persuasion standpoint and a weakly supported pitch from an evidence standpoint, at least based on the transcript excerpt. The copy is specific where it needs to be emotional: phone text, medicine labels, foggy road signs, night driving, faces, Sarah crying alone, and the fear of losing independence. It is also specific in its authority cues: Harvard, Johns Hopkins, pharmacology, pharmaceutical research. Those details give the video texture and credibility momentum.

But the most important claims remain under-documented. The VSL says vision loss is rooted in dormant regenerative cells, that four natural ingredients can wake them, that thousands of older people are seeing clearly again, and that people with serious symptoms or diagnoses may regain freedom from glasses, drops, and procedures. Those are extraordinary claims. The excerpt does not provide the product formula, dose, clinical trial, peer-reviewed human evidence, verified testimonials, or independent credential checks needed to support them.

For affiliates, the offer may convert because it speaks directly to a painful and urgent market. The angle is clear, the enemy is familiar, the hero story is emotionally accessible, and the Japanese kale mechanism is easy to remember. But promotion should be handled carefully. Avoid repeating unverified disease-reversal language in ads, presell pages, email subject lines, or native placements. Do not imply that buyers can skip eye exams or replace prescribed treatment. Do not present experimental regeneration research as proof of the product.

For copywriters, the lesson is more nuanced. The VSL shows how to build a compelling health narrative by aligning mechanism, backstory, authority, and future pacing. It also shows how quickly a persuasive mechanism can outrun the evidence. A more defensible version of this campaign would narrow the promise to nutritional support, disclose the complete formula early, cite relevant human research honestly, and distinguish between general eye comfort, age-related nutritional support, and diagnosed eye disease.

The balanced verdict: Couve Japonesa is compelling as a direct-response story, but the transcript makes claims that should be treated as unproven unless the full offer supplies much stronger evidence. Japanese kale and green vegetables may belong in a healthy diet. Nutrients such as lutein and zeaxanthin have legitimate eye-health relevance in specific contexts. Retinal regeneration research is real and exciting. None of that proves this VSL’s central promise of natural vision regeneration. The pitch deserves attention from marketers, but caution from anyone evaluating it as a health claim.